Spain moves to decentralise medtech R&D (research and development) with new E9 million centre:
This article was originally published in Clinica
Spain is to establish a new national regenerative medicine research centre in Barcelona, in line with a new national policy to decentralise healthcare R&D. Under an agreement signed between the Spanish health ministry and the Catalan regional government, the centre will be responsible for creating stem cell lines of embryonic and adult origin, as part of a national R&D programme that it will be responsible for devising in this area. The centre will be based at the biomedical research park of Barcelona (RRBB) and receive central funding totalling euro9m ($10.9m) by 2007.
You may also be interested in...
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.